Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., incorporated on December 10, 2007, is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout that durably controls uric acid in refractory gout, and dissolves and removes harmful deposits of uric acid crystals in chronic tophaceous gout. SEL-212 is in a Phase I/II clinical program. The Phase I/II clinical program consists of two Phase I clinical trials and a Phase II clinical trial and is designed to evaluate the ability of SEL-212 to control uric acid levels and mitigate the formation of ADAs. SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase, for the treatment of refractory and chronic tophaceous gout. SVP-Rapamycin uses its SVP technology to encapsulate the immunomodulator rapamycin in biodegradable nanoparticles.